|
Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inboxGmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscriptionClick this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
This Month's Featured News
Up Over 200% in 2026, What's Next for AI Stock Aehr Test Systems?Reported by Leo Miller. Article Published: 4/10/2026. 
Key Points
- AEHR has skyrocketed in 2026, being among the market's top performers.
- The company is generating orders and interest from many corners of the AI infrastructure market, exciting investors.
- The company's momentum in winning deals points to good things ahead, but AEHR's valuation remains a key risk.
- Special Report: Elon Musk: This Could Turn $100 into $100,000
Aehr Test Systems (NASDAQ: AEHR), a small company in the semiconductor industry, has been undeniably one of the market’s top performers in 2026. So far this year, AEHR is one of just five stocks in the Russell 3000 Index to deliver a return of more than 200%. Understanding the scope of the Russell 3000 helps put that performance in perspective. The index tracks the 3,000 largest U.S. stocks, representing roughly 98% of the investable U.S. equity market, and is widely viewed as the most comprehensive gauge of the U.S. stock market. That makes Aehr’s outperformance this year all the more notable. The company, which makes equipment that stress-tests semiconductor performance, has announced multiple deals throughout the year. Despite mixed results in its latest earnings report, the stock surged nearly 26% after the release. Here’s what’s fueling Aehr’s gains and what investors should consider going forward. Silicon Photonics Deal Boosts AEHR Stock
Analyst Jim Rickards believes gold could climb to $10,000 per ounce or higher in the coming years - and he says investors still have time to position ahead of the move.
His top recommendation is a $2 stock he describes as sitting on the largest gold deposit in the world, with an extraction green light potentially arriving April 15. See Jim Rickards' number one gold recommendation for 2026
Most of Aehr’s 2026 gain has occurred in a very short period. The stock began the year near $20 and was around $30 at the end of March. After that, shares more than doubled and moved above $65. March 31 was a key catalyst, when the stock jumped more than 23% following another customer win. The company announced a new silicon photonics customer that has ordered multiple FOX‑XP systems. Aehr described the customer as “a global leader in networking products and solutions and a major supplier to the data center optical transceiver market.” That matters because optical transceivers are critical components being rapidly adopted in AI data centers. As data processing demands grow, optical transceivers enable higher-speed, higher-volume data transfer. Companies such as Coherent (NYSE: COHR) and Lumentum (NASDAQ: LITE), which supply optical transceivers, have seen substantial share-price appreciation recently. For Aehr, gaining traction in this expanding market is a meaningful strategic win. Aehr also indicated that follow-on orders are possible in 2026. Importantly, the customer is buying systems for both engineering qualification and high-volume production. Customers typically qualify systems before ramping production, but doing both simultaneously signals confidence in Aehr’s technology and a sense of urgency from the buyer — factors that increase the likelihood of additional orders. Aehr Looks Poised to See Significant Growth in Fiscal 2027In its latest quarter, Aehr reported revenue of $10.3 million, missing estimates of $10.85 million. The company’s loss per share of $0.05, however, was smaller than the $0.07 analysts expected. Aehr reiterated guidance of $25 million to $30 million in revenue for the second half of fiscal 2026 (FY2026) and maintained an adjusted loss-per-share outlook of $0.09 to $0.05. Note that Aehr just reported Q3 FY2026 results; its fiscal year is offset from the calendar year. The more compelling story looks beyond the quarter. Aehr recorded bookings of $37.2 million during the period — more than 3.5 times its reported revenue — which points to larger revenues ahead. The company now expects second-half FY2026 bookings to be at the high end of its $60 million to $80 million range. Its effective backlog also reached a record $50.9 million, slightly above the high end of its FY2026 revenue guidance. That backlog provides a meaningful foundation for revenue growth into FY2027. AEHR Continues to Show It Is Not a Name to IgnoreOverall, Aehr continues to demonstrate an ability to win customers and orders. It has relationships with an AI-processor developer and with silicon-photonics customers — two areas experiencing strong, growing demand. The company is also in discussions with another AI-processor supplier, several high-bandwidth memory companies, and a NAND flash supplier. These memory and interconnect technologies are among the fastest-growing segments in AI infrastructure. It’s hard to call the stock cheap: AEHR’s market capitalization is above $2 billion, while FY2026 sales are expected to be no more than about $50 million. That valuation leaves meaningful downside risk given how far the shares have run. Still, Aehr’s recent customer wins and growing backlog mean future deals could propel further gains. Notably, analysts at Craig Hallum upgraded AEHR from Hold to Buy after the company’s latest results and set a $68 price target — a level the stock exceeded soon afterward. |
Post a Comment
0Comments